摘要
目的探讨TA方案在局部晚期乳腺癌新辅助化疗应用中的临床疗效。方法对84例局部晚期乳腺癌采用新辅助化疗TA方案,共2～4个周期,分别测量化疗前后肿瘤体积的变化,评价疗效。结果新辅助化疗后84例中,临床完全缓解5例,部分缓解58例,无效19例,进展2例,总有效率75%。未发生严重毒副反应。结论TA方案是局部晚期乳腺癌新辅助化疗有效的方案,具有降低肿瘤分期,增加根治和保乳手术机会,值得临床推广。
[Objective ] To evaluate the clinical efficacy of TA （Paclitaxel＋Adriamycin） in neoadjuvant chemotherapy for locally advanced breast cancer（LABC）. [Methods] 84 cases with LABC were treated with TA regimen 2 to 4 cycles. The effect of TA regimen was assessed through the tumor volume variations. [Results] Among 84 cases received TA regimen, 5 cases were in complete response （CR）, 58 cases were in partial response （PR）, 19 cases were in no change （NC） and 2 cases presented as progressive disease （PD）. Total response rate （CR＋PR） is 75%. No one had severe side effects. [Conclusion] The combination of Paclitaxel and Adfiamycin （TA） is an effective regimen as neoadjuvant chemotherapy for the LABC. It can decrease the staging of tumors, enhance the chances of radical mastectomy and breast-conserving therapy. It has a good prospect of clinical application.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2006年第13期2021-2022,2025,共3页
China Journal of Modern Medicine
关键词
乳腺癌
新辅助化疗
breast cancer
, neoadjuvant chemotherapy
